Treating active ankylosing spondylitis - NICE TA829
NICE TA829 - Upadacitinib for treating active ankylosing spondylitis
MHRA Drug Safety Update, 26 April 2023
1.1 Upadacitinib is recommended as an option for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults, only if:
tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and
the company provides upadacitinib according to the commercial arrangement.